May 12, 2021

PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update

• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months
Apr 29, 2021

PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021

PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 2021 financial
Feb 23, 2021

PolyPid to Participate in Upcoming Investor Conferences

PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond James 42 nd
Feb 16, 2021

PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

Top-line Data Anticipated by Year End   2021 Enrollment Also Continues to Progress in   Company’s Second Phase 3 Clinical Trial ,   SHIELD I I PETAH TIKVA, Israel , Feb. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical
Feb 10, 2021

PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

100   Patient s Enrolled into Phase 3 SHIELD I and SHIELD II   Trial s   of D-PLEX 100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX 100 for Prevention of SSIs in P atients U ndergoing E lective C olorectal S urgery
Jan 27, 2021

PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021

PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >